Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

Hepatology

Volumn 45, Issue 5, 2007, Pages 1154-1163

  Fontana, Robert J ^a,g   Bieliauskas, Linas A ^b,c   Lindsay, Karen L ^d   Back Madruga, Carla ^d   Wright, Elizabeth C ^e   Snow, Kristin K ^f   Lok, Anna S F ^a   Kronfol, Ziad ^b   Padmanabhan, Latha ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f NEW ENGLAND RESEARCH INSTITUTES   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DEPRESSION INVENTORY; EMOTIONAL STRESS; FEMALE; HEPATITIS C; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOOD; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AFFECT; ANTIVIRAL AGENTS; COGNITION; COGNITION DISORDERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 34248642022     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21633     Document Type: Article

References (50)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
2. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140;346-355.
3. Shifffman ML, DiBisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126:1015-1023.
4. Lee SS, Peltekian K, Krajdens M, Yoshida EM, Deschenes M, Heathcote EJ, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23:397-408.
5. Fried MW, Russo MA. Side effects of antiviral therapy for hepatitis C. Gastroenterology 2003;124:1711-1719.
6. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000;18;107-116.
7. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EZ, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003;9:847-854.
8. Weissenborn K, Krause J, Bokemyer M, Hecker H, Schuler A, Anen JC, et al. Hepatitis C virus infection affects the brain: evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004;41:845-851.
9. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok ASF, et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005;43:614-622.
10. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-439.
11. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005;41:801-808.
12. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C trial: pegylated interferon as a maintenance therapy for chronic hepatitis C in previous Interferon nonresponders. Control Clin Trials 2004;25:472-492.
13. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancel. JAMA 1984; 252-.938-941.
14. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676.
15. Wittchen HU. Reliability and validity studies of the WHO composite international diagnostic interview: a critical review. J Psychiatr Res 1994; 28:57-84.
16. Skinner HA, Sheu WJ. Reliability of alcohol use indices: the lifetime drinking history and the MAST. J Stud Alcohol 1982;43:1157-1170.
17. Bieliauskas L, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok ASF, et al. Clinical relevance of cognitive scores in patients with advanced fibrosis. J Clin Exp Neuropsychol 2006;28:1346-1361.
18. McCaffrey RJ, Ortega A, Orsillo SM, Nelles WB, Haase RF. Practice effects in repeated neuropsychological assessments. Clin Neuropsychol 1991;6:32-42.
19. Zachary RA. Shipley institute of living scale. Los Angeles: Western Psychological Services, 1991:1-35.
20. Beck AT, Steer RA, Brown GK. BDI-II Manual. The Psychological Corporation. San Antonio, TX: Harcourt Brace and Company, 1996:1-20.
21. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med 1983;3:595-605.
22. U.S. Census Bureau, Population Division, Education & Social Stratification Branch. Maintained by: Information & Research Services Internet Staff (Population Division). Created: March 15, 2004.
23. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis RJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology 1995;45:947-950.
24. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990;26:596-600.
25. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.
26. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676.
27. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152:383-389.
28. Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006;41:577-585.
29. Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, et al. Neurotoxicity of interferon-a in melanoma therapy: results from a randomized controlled trial. Cancer 1998;83:482-489.
30. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DK. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996;8:74-81.
31. Amodio P, De Toni EN, Cavalletto L, Mapelli D, Bernardinello E. Del Piccolo F, et al. Mood, cognition and EEG changes during interferon α (alfa-IFN) treatment for chronic hepatitis C. J Affect Disord 2005;84:93-98.
32. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon a on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005;11:16-22.
33. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003;9:419-428.
34. Lemay S, Bedard M, Roleau I, Tremblay P. Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects. Clin Neuropsychol 2004;18:284-302.
35. McCaffrey RJ, Ortega A, Orsillo SM, Neiles WB, Haase RF. Practice effects in repeated neuropsychological assessment. Clin Neuropsychol 1992;6:32-42.
36. Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol 1985;7:251-263.
37. Basso MR, Bornstein RA, Lang JM. Practice effects of commonly used measures of executive function across twelve months. Clin Neuropsychol 1999;13:283-292.
38. Beglinger LJ, Crawford-Miller, Kareken DA. Neuropsychological practice effects and change detection in people with schizophrenia. Schizophr Res 2003;62:191-194.
39. Paradee CV, Rapport LJ, Hanks RA, Levy JA. Circadian preference and cognitive functioning among rehabilitation inpatients. Clin Neuropsychol 2005;19:55-72.
40. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al. Depression, anemia, and health-related quality of life in chronic hepatitis C. J Hepatol 2006;44:491-498.
41. Benedict RHB, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004;10:675-678.
42. Randolph JJ, Arnett PA, Freske P. Metamemory in multiple sclerosis: Exploring affective and executive contributors. Arch Clin Neuropsychol 2004;19:259-279.
43. Elixhauser A, Leidy NK, Meador K, Means E, Willan MK. The relationship between memory performance, perceived cognitive function and mood in patients with epilepsy. Epilepsy Res 1999;37:13-24.
44. Banos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, et al. Self-report of cognitive abilities in temporal lobe epilepsy:cognitive, psychosocial, and emotional factors. Epilepsy Behav 2004;5:575-579.
45. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-39.
46. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Knguid C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002;76:600-608.
47. Mayr N, Zeithofer J, Deecke L, Fritz E, Ludwig H, Gisslinger H. Neurological function during long-term therapy with recombinant interferon-alpha. J Neuropsychiatry Clin Neurosci 1999;11:343-348.
48. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive function in multiple sclerosis. Eur Neurol 2002;47:11-14.
49. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann HL, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624-1630.
50. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-a induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10:538-544.